Drug‐eluting bead chemoembolization for the treatment of nonresectable hepatic carcinoma in dogs: A prospective clinical trial. (6th May 2021)

• Record Type: Journal Article
• Authors: Rogatko, Cleo P.; Weisse, Chick; Schwarz, Tobias; Berent, Allyson C.; Diniz, Marcio A.
• Is Part Of: Journal of veterinary internal medicine. Volume 35:Number 3(2021)
• Page Start: 1487
• Page End: 1495
• Publication Date: 2021-05-06
• Subjects: DEB -- doxorubicin -- interventional radiology -- liver -- TACE; Veterinary medicine -- Periodicals; 636.0896
• DOI: 10.1111/jvim.16109
• Languages: English
• ISSNs: 0891-6640

Abstract

Abstract: Background: Effective treatment options for nonresectable hepatic carcinoma (HC) in dogs are limited. Hypothesis/Objective: Objectives were to report outcomes, complications, and tumor responses via computed tomography (CT) assessment after drug‐eluting bead transarterial chemoembolization (DEB‐TACE) for nonresectable HC in dogs. The authors hypothesized that major complications would be uncommon and short‐term CT assessment would demonstrate stable disease or partial response. Animals: Client‐owned dogs (n = 16) with nonresectable HC. Methods: Prospective, single‐arm clinical trial. Drug‐eluting bead transarterial chemoembolization was performed to varying levels of blood flow stasis. Computed tomography imaging was compared before and approximately 12 weeks after initial treatment. Results: Drug‐eluting bead transarterial chemoembolization was successfully administered in all attempts. Based on percent change in elliptical tumor volume response (mL), stable disease (8/13; 62%) was the most common outcome followed by partial response (3/13; 23%) and progressive disease (2/13; 15%) with a median of 74 days (range, 39‐125) after initial treatment. Median tumor volume (mL) after DEB‐TACE decreased in volume by 13% (range, 56% decrease to 77% increase). Mild complications consistent with postembolization syndrome occurred after 7/27 (26%) treatments. Major complications occurred after 3/27 (11%) treatments: hepatic abscess/septicemia (2) and cholecystitis/death (1), resulting in treatment‐induced death after 2/27 (7%) treatments. Median survival time after treatment was 337 days (range, 22‐1061). Dogs with a presenting complaint of weight loss ( P = .02) had a significantly shorter median survival time (126 days; range, 46‐337) than those dogs without prior history of weight loss (582 days; range, 22‐1061). Conclusions: Drug‐eluting bead transarterial chemoembolization for nonresectable HC is a feasible procedure, which promoted stable disease or partial response in 85% of dogs in this study sample.